Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28943323 | 0.79 | LMNA (0.41) | NOTUMLMNABLMKDM1A | |
| SCHEMBL2466865 | 0.73 | KDM1A (0.43) | KDM1A | |
| Fumaric Acid SCHEMBL28943372 | 0.72 | LMNA (0.53) | LMNABLM | |
| SCHEMBL7351257 | 0.71 | KMT2A (0.40) | LMNABLM | |
| SCHEMBL7824370 | 0.71 | LMNA (0.43) | LMNABLM | |
| SCHEMBL9054248 | 0.70 | KDM1A (0.45) | KDM1A | |
| SCHEMBL9053824 | 0.70 | KDM1A (0.41) | KDM1A | |
| SCHEMBL6071126 | 0.70 | GAA (0.40) | LMNABLM | |
| SCHEMBL15609154 | 0.70 | LMNA (0.36) | LMNABLM | |
| SCHEMBL7737636 | 0.70 | SIGMAR1 (0.37) | LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |